Background: Schizophrenia is a complex mental disease whose cause is still un-
| INTRODUCTION
Schizophrenia, a serious mental illness, is characterized by the disharmony between mental activity and the realistic environment, the disharmony and disintegration of cognition, emotion, volition, and so forth. It has shortened the lifespan and afflicts about 1% of the population all over the world (Leucht, Burkard, Henderson, Maj, & Sartorius, 2007) . Symptoms typically occur in late adolescence or early adulthood. Not surprisingly, the financial burden of this disease is considerable. But so far, the etiology of schizophrenia remains unknown and is still in the exploratory stage. There was no theory that could perfectly explain the pathogenesis of schizophrenia. It is generally believed that the occurrence of schizophrenia is mainly influenced by environment and genetic background, among which genetic factors account for 80%. Family and twin studies of schizophrenia found that the prevalence of relatives was significantly higher than that of the general population. The heritability of schizophrenia and bipolar disorder is between 70% and 80%, with major depressive disorder up to 40% (Uher, 2014) .
Over the past few decades, a link between genetic polymorphisms and schizophrenia has been proposed. Numerous researchers are trying to understand the association of genetic polymorphism with schizophrenia to understand the etiology of schizophrenia. Recently there has been a greater focus on candidate gene CHRNA5 (OMIM#118505) encoding the α5 subunit of nicotinic acetylcholine receptors (nAChRs) in the studies of schizophrenia pathophysiology. CHRNA5 is located in 15q25.1 and belongs to the superfamily of ligand-gated ion channels that mediated fast signal transmission at synapses. The present study follows up on data reported by some researchers by examining CHRNA5 polymorphisms and lung cancer risk in the population (Huang et al., 2015; Shen et al., 2013; Xu et al., 2015) , suggesting that genetic variation in CHRNA5 may affect susceptibility to lung cancer among smokers. But, few studies have been reported in the correlation between CHRNA5 polymorphisms and schizophrenia.
To examine whether CHRNA5 may also contribute to schizophrenia in a Chinese population, we selected eight variants in CHRNA5 to perform a case-control study. Herein, the results reported may help in future studies of schizophrenia and contribute to easing the burden of this disease on individuals, families, and society.
| MATERIALS AND METHODS

| Ethical compliance
All participants have been informed both verbally and in writing of the procedures and purpose of this study and they signed informed consent documents. This study protocol was approved by the Clinical Research Ethics Committees of Psychiatric Hospital of Xi'an. All the subsequent research analyses were carried out in accordance with Department of Health and Human Services (DHHS) regulations for human research subject protection.
| Study subjects
We recruited 384 schizophrenia patients from Psychiatric Hospital of Xi'an, Shaanxi province and 687 volunteers were considered as controls to conduct a case-control study. On the basis of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, the fourth version), all patients were diagnosed and pathologically confirmed by the experienced senior psychiatrists to suffer from schizophrenia. The patients had no history of other related diseases, including cancer, nephropathy, and so on. Also, there were no sex, age, and/ or stage restrictions for cases and none of the healthy control subjects had any mental illness. Besides, all the participants were genetically unrelated ethnic Han Chinese.
| SNP selection and genotyping
On the basis of the dbSNP database, we randomly selected eight candidate polymorphisms (rs667282, rs16969948, rs588765, rs6495306, rs17486278, rs680244, rs569207, and rs692780) in CHRNA5 (its GenBank reference is NC_000015.10). Each SNP had minor allele frequency (MAF)> 5% in the global population from 1,000 Genome Projects (http://www.inter natio nalge nome.org/). Then Regulome DB (http://www. regul omedb.org/) and HaploReg were utilized to predict the function of SNPs. We used the Genotype-Tissue Expression (GTEx) projects (https ://gtexp ortal.org/home/) expression quantitative trait loci (eQTL) variants to assess the effects of schizophrenia-associated SNPs on gene expression. Genomic DNA was extracted from blood samples using the GoldMagMini Whole Blood Genomic DNA Purification Kit (GoldMag Ltd. Xi'an City, Shaanxi, China). NanoDrop2000 (Thermo Scientific, Waltham, Massachusetts, USA) was used to check the quantification of the extracted DNA at a wavelength value of A260 nm. We used the Agena MassARRAY Assay Design 3.0 Software (San Diego, CA) to design Multiplexed SNP MassEXTEND assays and genotyped the variants using the MassARRAY iPLEX (Agena Bioscience) platform using the matrix-assisted laser desorption ionization-time of flight (MALDITOF). Data management and analysis was conducted by the Agena Typer 4.0 software (San Diego, CA). 
| Statistical analyses
| RESULTS
| Characteristics of case and control
Of the 1,071 samples (588 men and 483 women), 384 were classified as schizophrenia cases (201 men and 183 women), and 687 were classified as controls (300 men and 387 women) in the study. The average age of the initially diagnosed schizophrenia and normal people was 36.58 ± 13.733 years and 48.56 ± 9.559 years, respectively.
| The association between CHRNA5
SNPs and schizophrenia risk
We successfully genotyped eight SNPs listed in Tables 1 and  2 . The Regulome DB scores and HaploReg were the function of the selected SNPs shown in Table 1 . We analyzed the data, including four gene models (codominant, dominant, recessive, and additive models) to explore the correlation between SNPs and schizophrenia by logistic regression analysis with adjustment for age and gender. Eight variants (rs667282, rs16969948, rs588765, rs6495306, rs17486278, rs680244, rs569207, and rs692780) in the CHRNA5 were found to be risk factors, but, there were no significant differences.
| Stratification analysis by gender and age
We reanalyzed the case-control association study by gender stratifying. In Table 3 , after the adjustment for age, the frequency of the homozygous "C/C" genotype of rs17486278 (HGVS: NM_000745.3:g.78575140A>C) differed significantly between schizophrenia patients and controls (4.4% vs. 7.7%) in females. The variant was associated with a decreased risk of schizophrenia in the recessive model (adjusted OR = 0.37, 95%CI: 0.15-0.93) with power values of 0.982 in females. Moreover, we found that the four variants rs588765, rs6495306, rs680244, rs692780 were significantly linked to the risk of schizophrenia after adjusted by ≥45 years (Table 4 ), but none of the sites exhibilited the association with schizophrenia risk with adjustment by <45 years. The four SNPs were noteworthy before and after the adjustment. The rs588765 (HGVS: NM_000745.3:g.78573083T>C) and rs680244 (HGVS: NM_000745.3:g.78578946T>C) genotype for "C/T" subjects were linked to an increased risk of schizophrenia based on the results of the codominant model (adjusted OR = 2.12, 95%CI: 1.36-3.30, p = .003; adjusted OR = 1.70, 95%CI: 1.09-2.67, p = .027, respectively) with power values of 0.879 and 0.646, respectively. In addition, allele "T" of the rs588765 and rs680244 significantly increased the risk of schizophrenia in the dominant model (adjusted OR = 2.12, 95%CI: 1.38-3.25, p = 6e-04; adjusted OR = 1.77, 95%CI: 1.15-2.71, presented an increased contribution to the risk of schizophrenia in the codominant model (adjusted OR = 2.12, 95%CI: 1.36-3.30, p = .003; adjusted OR = 2.07, 95%CI: 1.33-3.22, p = .005) with power values of 0.879 and 0.862, respectively. An association between allele "G" of rs6495306, allele "C" of rs692780, and an increased risk of schizophrenia were observed based on the dominant model (adjusted OR = 2.12, 95%CI: 1.38-3.25, p = 6e−04; adjusted OR = 2.02, 95%CI: 1.32-3.10, p = .001; respectively) with power values of 0.879 and 0.838, respectively. The two sites in the log-additive model showed similar results. In addition, GTEx results (Table S1) showed that the statistically significant variants (rs17486278, rs588765, rs6495306, rs680244, rs692780) were associated with CHRNA5 gene expression in the most relevant tissue (brain).
| Linkage disequilibrium analysis and haplotypes
Then we used linkage disequilibrium analysis to detect the correlation between CHRNA5 SNPs, shown in Figures  1 and 2 . In Figure 2 , aside from rs16969948 (HGVS: NM_000745.3: g.78572444A>G), the significant association among other variants still existed in females. However, after stratifying analysis by ≥45 years, there existed higher linkage among eight CHRNA5 SNPs (Figure 2) .
Eventually, haplotype analysis was done in eight SNPs (rs667282, rs16969948, rs588765, rs6495306, rs17486278, rs680244, rs569207, and rs692780) and displayed five haplotypes in our controls and patients (Table 5) . We found that the haplotype "TATGATCC" was linked to a higher risk of schizophrenia without or with adjustment by age and gender. 
T A B L E 2 Basic information and allele frequencies of the SNPs in CHRNA5
SNP
| DISCUSSION
In our study, we investigated the correlations between eight CHRNA5 SNPs and schizophrenia risk. Rs17486278 showed a significant association with decreased susceptibility of schizophrenia in females and males. After being stratified by ≥45 years, CHRNA5 variants (rs588765, rs6495306, rs680244 and rs692780) were associated with an increased risk of schizophrenia. So, we deduced that the polymorphisms of CHRNA5 may influence susceptibility to lung cancer among the Chinese populations. The current antipsychotics mainly alleviate neurotransmitter imbalance, but most patients still have relapse in the current treatment plan (Leucht et al., 2013 (Leucht et al., , 2009 decades, pathophysiological studies related to schizophrenia were greatly focused on interfering with dopaminergic and glutamatergic neurotransmission to achieve the treatment of schizophrenia. CHRNA5 is a member of nAChRs typically expressed in the nervous system and involved in various functional processes, including cognition, learning, memory, and so forth. Moreover, alterations in their expression and/or activity have been implicated in various neurological disorders, such as Alzheimer's disease (AD) (Dineley et al., 2001 ), Parkinson's disease (Xie, Gao, Xu, & Meng, 2014) , and schizophrenia (Freedman, Adams, & Leonard, 2000) . In general, nAChRs form a family composed of ligand-gated cationic channels, activated by the endogenous neurotransmitter acetylcholine (ACh), carbachol, and nicotine to promote tumor development (Hung et al., 2008) . In knockout mouse studies of Chrna5, mRNA expression in habenular and ventral tegmental area, mice with a null mutation for Chrna5 significantly increased nicotine intake by modulating the sensitivity of dopaminergic neurons (Fowler, Lu, Johnson, Marks, & Kenny, 2011; Morel et al., 2014) . In the medial habenula, Chrna5 overexpression can reduce nicotine consumption to wild-type levels (Fowler et al., 2011) , illustrating that CHRNA5 mediates negative reward signaling through the habenulo-interpenduncular pathway in the habenula. Notably, polymorphisms located in a cluster of genes coding for the subunits α5, α3, and β4 of nAChR were related to various health problems (Bierut, 2010) . CHRNA5 rs16969968 was reported to interact with a splicing SNP in the dopamine D2 receptor gene (DRD2) involved in addiction (Moyer et al., 2011) to influence multiple aspects of prefrontal cortex physiology and behavior during working memory (Di Giorgio et al., 2014) , suggesting that CHRNA5 had a pervasive functional profile in brain regions central to cognition. Also, the previously reported studies have demonstrated that CHRNA variants have been linked to increased risk of lung cancer amongst Han individuals (He et al., 2014; Le Marchand et al., 2008; Niu et al., 2010; Thorgeirsson et al., 2008; Zhou et al., 2015) . But, CHRNA3 (OMIM#118503) polymorphisms were found to contribute to an increased risk of lung cancer in the Han individuals who smoke (Zhou et al., 2015) , however, CHRNA3 variant (rs8042374, NM_000743.4:g.78615690A>G) was linked to a greater risk of lung adenocarcinoma in female nonsmokers (He et al., 2014) . Thus, the effect of smoking on the risk of lung diseases is not essential.
In our study, our case-control data provided statistical evidence for a strong association between CHRNA5 (rs17486278, rs588765, rs6495306, rs680244, rs692780) and schizophrenia risk. Among them, rs17486278 was found to be an increased variant associated with lung cancer risk in African Americans and European populations (Broderick et al., 2009; Hansen et al., 2010) . In a never-smoking Chinese population study, the association between rs17486278 in gene cluster CHRNA5-CHRNA3-CHRNB4 and nonsmall cell lung cancer (NSCLC) was not significant (Li, Bao, Xu, Bao, & Zhang, 2012) . While we evaluated the relationship between rs17486278 and lung cancer risk, it was consistent with the previous results of the Chinese population (Huang et al., 2015) . The main reason for this difference should be racial differences. The SNP had no significance in males, but was statistically significant in females, so, the result of rs17486278 is different for gender differences.
Moreover, two variants (rs588765 and rs680244) have been reported to be correlated with an increased risk of lung cancer (Huang et al., 2015) . Rs588765 and rs680244 were also associated with neuroticism (Criado, Gizer, Edenberg, & Ehlers, 2014) . In this study, we firstly provide a new evidence that rs588765 and rs680244 appeared to be related to an increased schizophrenia risk in Shaanxi Han population study. But, having additional large sample series is necessary for further verification results to become more credible.
| CONCLUSIONS
In conclusion, our results obtained from a cohort of Chinese schizophrenia patients illustrated that CHRNA5 SNPs (rs17486278, rs588765, rs6495306, rs680244, rs692780) were significantly associated with schizophrenia risk. Hence, it may potentially serve as a clinically prediagnostic marker.
T A B L E 5 Haplotype analysis between CHRNA5
haplotypes and schizophrenia risk 
